Vivace Therapeutics
$35.0M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Vivace Therapeutics is currently valued at $125.0M as of February 28, 2025. The company has raised a total of $105.0M in funding.
Capital Efficiency
With a capital efficiency ratio of 1.19x, Vivace Therapeutics has achieved a valuation that is 1.19 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
Vivace Therapeutics's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Vivace Therapeutics Worth in 2025?
As of 2025, Vivace Therapeutics is valued at $125.0M, based on the company's Later Stage VC funding round in February 28, 2025. This valuation positions Vivace Therapeutics as one of the leading private companies in the sector.
Vivace Therapeutics Valuation History
Vivace Therapeutics's funding history demonstrates steady growth and investor confidence.
How Vivace Therapeutics Valuation is Determined
Private company valuations like Vivace Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Vivace Therapeutics Valuation FAQs
Is Vivace Therapeutics profitable?
Vivace Therapeutics has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Vivace Therapeutics's valuation compare to competitors?
Vivace Therapeutics is valued at $125.0M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Vivace Therapeutics IPO?
Vivace Therapeutics has not announced plans for an initial public offering. Until an IPO, investors can access Vivace Therapeutics shares through secondary market platforms.